Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after...
-
TORONTO and CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The...
-
TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at...
-
TORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive...
-
TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive...
-
NDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline)Final FDA decision expected 2 to 6 months after NDA resubmissionNo additional Phase III study is required ...
-
Achieved $17.9 million revenue driven by continued strength of Rupall™ Positioned for revenue growth along with expected recovery of IXINITY® sales Commercially launched Trecondyv® (treosulfan) in...
-
TORONTO and CHICAGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that management will present at the Q4...
-
TORONTO and CHICAGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown...
-
TORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at...